Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens

Emilio Bajetta(Fondazione Lanza), Roberto Buzzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Elena Magnani(Fondazione IRCCS Istituto Nazionale dei Tumori), L. Somma(Luigi Sacco Hospital), P. Bignami(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), F. Zunino(Fondazione IRCCS Istituto Nazionale dei Tumori), Salvatore Artale(Ospedale San Carlo)
European Journal of Cancer
April 1, 1997
10.1016/s0959-8049(96)00491-1
Cited by 13

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912